HUMA Humacyte, Inc.
Healthcare$1.05+2.94%ClosedMarket Cap: $176.4M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
17.87
P/S
87.50
EV/EBITDA
-1.73
DCF Value
$-0.02
FCF Yield
-58.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-748.5%
Operating Margin
-5649.2%
Net Margin
-4840.8%
ROE
-2781.6%
ROA
-88.3%
ROIC
-117.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $495.0K | -311.7% | $-28.9M | $-17.6M | $— | — |
| Q4 null | $467.0K | -2227.6% | $-30.8M | $-24.8M | $— | — |
| FY null | $2.0M | -736.5% | $-107.4M | $-40.8M | $— | — |
| Q3 null | $753.0K | -182.2% | $-24.4M | $-17.5M | $— | — |
| Q2 null | $301.0K | -588.7% | $-29.7M | $-37.7M | $— | — |
| Q1 null | $517.0K | -282.8% | $-23.2M | $39.1M | $— | — |
| Q4 null | $7.2M | 50.0% | $-28.1M | $-20.9M | $— | — |
| FY null | $0.00 | -Infinity% | $-114.4M | $-148.7M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-30.2M | $-39.2M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-29.5M | $-56.7M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-26.6M | $-31.9M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-26.2M | $-25.1M | $-0.24 | — |